Overview
June 8, 2007
Pittsburgh, PA
Statement of Need/Program Overview
Emerging treatments and advances in oncology are 1-day symposia designed to update practicing medical, surgical, radiation oncologists; hematologists; nurses; and other clinicians with an integration of important clinical data presented at the 2007 Annual Meetings of the American Society of Clinical Oncology. This series has been designed to update physicians on recent advances and new treatment modalities in the management of thoracic, breast, gastrointestinal, hematological malignancies, prostate and renal cancer and other solid tumors, with key data on novel therapeutic agents. This interactive meeting will include didactic sessions, panel and interactive discussions from known thought leaders who will offer their recommendations about the clinical challenges that practicing physicians’ face in their daily practice. These meetings are conducted in selected US cities, and are highly accessible to oncologists/hematologists practicing locally.
Target Audience
These symposia are directed toward medical, surgical, and radiation oncologists; hematologists; and fellows practicing in the community or academic institutions. Nurses, physicians’ assistants, and other individuals interested in the treatment of cancer are also invited to attend. The overall goal of this activity is to update attendees on new developments reported at the 2007 Annual Meetings of the American Society of Clinical Oncology.
Learning Objectives
Upon completion of this activity, you should be able to:
- Correlate chemotherapy and targeted agent combinations in the treatment of newly diagnosed and advanced Non−small-cell lung cancer
- Identify novel molecular-targeted therapies for lung cancer, including novel EGFR inhibitors, angiogenesis inhibitors, HDAC inhibitors, proteasome inhibitors, multitargeted tyrosine kinase inhibitors, and vaccines
- Evaluate the use of novel targeted agents, such as inhibitors of the VEGF or ErbB signaling pathways, in patients with advanced breast cancer
- Discuss optimization strategies for adjuvant endocrine therapy and management of side effects in patients with breast cancer
- Review the therapeutic potential and safety of chemotherapeutic regimens in combination with angiogenesis inhibitors and novel anti-EGFR monoclonal antibodies in patients with colon cancer
- Assess newer therapeutic options available for the treatment of pancreatic cancer
- Evaluate the emerging role of Raf kinase inhibitors and multitargeted inhibitors in the treatment of hepatic cancer
- Summarize current therapeutic options in the form of chemotherapy, radiation therapy, and targeted agents for patients with head/neck cancer
- Review recent advances in the management of aggressive Non-Hodgkin’s lymphoma
- Assess the role of monoclonal antibodies and other novel agents in the treatment of Non-Hodgkin’s lymphoma and their potential for improving clinical outcomes
- Outline recent advances in the management of mantle cell lymphoma with monoclonal antibodies, HDAC inhibitors, and proteasome inhibitors
- Discern treatment options in the form of immunomodulatory agents, proteasome inhibitors, heat shock protein inhibitors, and novel formulations of anthracyclines for newly diagnosed and advanced multiple myeloma
- Define the role of tyrosine kinase inhibitors which lead to fundamental revision of therapeutic strategy to overcome resistance to initial therapy in patients with chronic myeloid leukemia
- Integrate multimodality treatment approaches of chemotherapy, radiation therapy, surgery, and hormonal therapy, into the management of patients with prostate cancer
- Integrate the use of multitargeted kinase inhibitors in the treatment of renal cell carcinoma
CME Accreditation
This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of Postgraduate Institute for Medicine (PIM) and International Lung Cancer Network. PIM is accredited by the ACCME to provide continuing medical education for physicians
Disclosure of Conflicts of Interest
Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by PIM for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.
Americans with Disabilities Act
Event staff will be glad to assist you with any special needs (ie, physical, dietary, etc). Please contact Roberta Granny prior to the live event at (412) 648-6619